Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food Effect Study of TAK-831 in Healthy Subjects
NCT03101293Phase 1Completed
- Sponsor
- Neurocrine Biosciences
- Start
- Apr 2017
- Primary completion
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of luvadaxistat in schizophrenia and Friedreich ataxia (FA) (2 arms), sponsored by Neurocrine Biosciences. Primary endpoints: Maximum Observed Plasma Concentration, Area Under the Plasma Concentration-time Curve From Time 0 to Last Quantifiable Concentration and 1 more. Started Apr 2017; status: completed.
02
Drugs
luvadaxistat
03
Conditions
schizophreniaFriedreich ataxia (FA)
Beyond the preview
Go deeper on NCT03101293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03101293.